News Releases

Date Title and Summary Additional Formats
Toggle Summary ChemoCentryx to Hold Fourth Quarter and Full Year 2021 Financial Results Conference Call on Tuesday, March 1, 2022
MOUNTAIN VIEW, Calif. , Feb. 23, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the Company's fourth quarter and full year 2021 financial results will be released after market close on Tuesday, March 1, 2022 . ChemoCentryx executive management will host a
View HTML
Toggle Summary ChemoCentryx to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
SAN CARLOS, Calif. , Feb. 09, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 11 th Annual SVB Leerink Global Healthcare Conference on Wednesday, February
View HTML
Toggle Summary ChemoCentryx Announces EU Approval of TAVNEOS® (avacopan) for the Treatment of ANCA-Associated Vasculitis
-- Launch Expected in H1 2022 -- SAN CARLOS, Calif. , Jan. 19, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that TAVNEOS ® (avacopan) has been approved within the European Union in combination with a rituximab or cyclophosphamide regimen for the treatment of adult
View HTML
Toggle Summary ChemoCentryx to Present at Two Upcoming Investor Conferences
SAN CARLOS, Calif. , Jan. 04, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences: 40th Annual J.P. Morgan Healthcare Conference Wednesday, January 12 at
View HTML
Toggle Summary Positive Recommendation for Use of TAVNEOS™ (avacopan) in ANCA Vasculitis Adopted by European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP)
SAN CARLOS, Calif. , Nov. 12, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorization for the Company’s TAVNEOS
View HTML
Toggle Summary ChemoCentryx to Participate in Two Upcoming Investor Conferences
SAN CARLOS, Calif. , Nov. 10, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences: Stifel 2021 Virtual Healthcare Conference Fireside Chat Wednesday,
View HTML
Toggle Summary ChemoCentryx Reports Third Quarter 2021 Financial Results and Recent Highlights
-- U.S. Food & Drug Administration (FDA) approves TAVNEOS TM (avacopan) in ANCA-Associated Vasculitis in October -- -- TAVNEOS now launched in the U.S. -- -- TAVNEOS approved also in Japan ; European CHMP opinion expected this month -- -- Pipeline advances: Company intends to meet with FDA on path
View HTML
Toggle Summary Abstracts at the Annual Meetings of the American Society of Nephrology and American College of Rheumatology Highlight Potential Value of TAVNEOS™ (avacopan)
SAN CARLOS, Calif. , Nov. 04, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced the abstracts accepted for presentation and publication as part of the annual meetings of the American Society of Nephrology (ASN) Kidney Week 2021 and American College of Rheumatology (ACR)
View HTML
Toggle Summary ChemoCentryx to Hold Third Quarter 2021 Financial Results Conference Call on Tuesday, November 9, 2021
MOUNTAIN VIEW, Calif. , Nov. 02, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the Company's third quarter 2021 financial results will be released after market close on Tuesday, November 9, 2021 . ChemoCentryx executive management will host a conference call and
View HTML
Toggle Summary ChemoCentryx Appoints Rita I. Jain, M.D. as Executive Vice President, Chief Medical Officer
Appointment Brings More than 20 Years of Drug Development Experience as Company Launches First Product SAN CARLOS, Calif. , Oct. 11, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced the appointment of Rita I. Jain , M.D., as Executive Vice President, Chief Medical
View HTML